**AMENDMENTS TO THE CLAIMS** 

Claims 8 and 21-23 are amended. A complete listing of the claims is provided below.

1-7 (Cancelled)

8. (Currently amended) A method for in vitro screening for a peptide capable of altering the

phenotype of a cell, said method comprising the steps:

a) introducing a molecular library of retroviral vectors comprising randomized nucleic acids into

a plurality of cells to provide for expression of a plurality of test peptides each comprising a randomized

amino acid sequence and a glycine N-terminal to said randomized amino acid sequence,

b) screening said plurality of cells for a cell exhibiting an altered phenotype due to an interaction

between a test peptide and a cellular protein that is not produced using a nucleic acid made using

recombinant DNA technology component native to said cell; and

c) identifying said peptide capable of altering the phenotype of said cell.

9. (Previously presented) A method according to claim 8 wherein said identifying comprises:

i) isolating said cell exhibiting an altered phenotype.

10. (Previously presented) A method according to claim 9 wherein said identifying further

comprises:

ii) sequencing said nucleic acid encoding said peptide capable of altering the phenotype

of said cell.

11. (Previously presented) A method according to claim 8 wherein said nucleic acids further

encode a presentation sequence capable of presenting said test peptides in a conformationally restricted

form.

12. (Previously presented) A method according to claim 8 wherein said cells are mammalian

cells.

2

USSN: 10/057,467

ATTY, DOCKET NO: RIGL-005CON

- 13. (Previously presented) A method according to claim 8 wherein said library comprises at least 10<sup>4</sup> different nucleic acids.
- 14. (Previously presented) A method according to claim 8 wherein said library comprises at least 10<sup>5</sup> different nucleic acids.
- 15. (Previously presented) A method according to claim 8 wherein said library comprises at least 10<sup>6</sup> different nucleic acids.
- 16. (Previously presented) A method according to claim 8 wherein said library comprises at least 10<sup>7</sup> different nucleic acids.
- 17. (Previously presented) A method according to claim 8 wherein said library comprises at least 10<sup>8</sup> different nucleic acids.
- 18. (Previously presented) A method according to claim 8 wherein said library comprises at least 10<sup>9</sup> different nucleic acids.
- 19. (Previously presented) A method according to claim 8 wherein each of said nucleic acids is linked to nucleic acid encoding at least one fusion partner.
- 20. (Previously presented) A method according to claim 19 wherein said fusion partner comprises a nuclear localization signal sequence.
- 21. (Currently amended) A method for in vitro screening for a peptide capable of altering the phenotype of a cell, said method comprising the steps:
- a) introducing a molecular library of retroviral vectors comprising randomized nucleic acids into a plurality of cells to provide for expression of a plurality of test peptides each comprising a randomized amino acid sequence;

USSN: 10/057,467

'ATTY. DOCKET NO: RIGL-005CON

b) screening said plurality of cells for a cell exhibiting an altered cell growth phenotype, wherein said altered phenotype is due to an interaction between a test peptide and a cellular <u>protein that is not produced using a nucleic acid made using recombinant DNA technology</u> component native to said cell; and

- c) identifying said peptide capable of altering the cell growth phenotype of said cell.
- 22. (Currently amended) A method for in vitro screening for a peptide capable of altering the phenotype of a cell, said method comprising the steps:
- a) introducing a molecular library of retroviral vectors comprising randomized candidate nucleic acids into a plurality of cells to provide for expression of a plurality of test peptides each comprising a randomized amino acid sequence;
- b) screening said plurality of cells for a cell exhibiting an altered cell death phenotype, wherein said altered phenotype is due to an interaction between a test peptide and a cellular <u>protein that is not produced using a nucleic acid made using recombinant DNA technology</u> component native to said cell; and
  - c) identifying said peptide capable of altering the cell death phenotype of said cell.
- 23. (Currently amended) A method for in vitro screening for a peptide capable of altering the phenotype of a cell, said method comprising the steps:
- a) introducing a molecular library of retroviral vectors comprising randomized candidate nucleic acids into a plurality of cells to provide for expression of a plurality of test peptides each comprising a randomized amino acid sequence;
- b) screening said plurality of cells for a cell exhibiting a change in expression of a cellular differentiation marker, wherein said change in expression is due to an interaction between a test peptide and a cellular <u>protein that is not produced using a nucleic acid made using recombinant DNA</u>

  <u>technology</u> component native to said cell; and
- c) identifying said peptide capable of changing expression of a cellular differentiation marker of said cell.
- 24. (Previously presented) The method according to claim 23, wherein said cellular differentiation markers are characteristic of T-cell activation.

USSN: 10/057,467 ATTY. DOCKET NO: RIGL-005CON

25. (Previously presented) The method according to claim 23, wherein said cellular differentiation markers are characteristic of B-cell activation.